Tissue plasminogen activator treatment of stroke in type-1 diabetes rats - Test2 - elhamkhani - TriplyDB

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

http://www.wikidata.org/entity/Q42132761

about

Neurorestorative Therapy of Stroke in Type 2 Diabetes Mellitus Rats Treated With Human Umbilical Cord Blood Cells.miR-145 Regulates Diabetes-Bone Marrow Stromal Cell-Induced Neurorestorative Effects in Diabetes Stroke Rats.Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke Endothelial progenitor cells transplantation attenuated blood-brain barrier damage after ischemia in diabetic mice via HIF-1α.Hyperglycemia, acute ischemic stroke, and thrombolytic therapy Diabetes mellitus aggravates hemorrhagic transformation after ischemic stroke via mitochondrial defects leading to endothelial apoptosis.Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.D-4F Decreases White Matter Damage After Stroke in Mice Intracranial aneurysm formation in type-one diabetes rats Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats.Neamine induces neuroprotection after acute ischemic stroke in type one diabetic rats Hyperglycemia in stroke and possible treatments.Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes.Autophagy protects human brain microvascular endothelial cells against methylglyoxal-induced injuries, reproducible in a cerebral ischemic model in diabetic rats.Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes.Diabetic aggravation of stroke and animal models.Blood-Brain Barrier Disruption, Vascular Impairment, and Ischemia/Reperfusion Damage in Diabetic Stroke.N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes.D-4F increases microRNA-124a and reduces neuroinflammation in diabetic stroke rats.Is shorter transient middle cerebral artery occlusion (t-MCAO) duration better in stroke experiments on diabetic female Sprague Dawely rats?Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.Rho-kinase and the nitric oxide pathway modulate basilar arterial reactivity to acetylcholine and angiotensin II in streptozotocin-induced diabetic mice.Cell-Based and Exosome Therapy in Diabetic Stroke.

P2860

Q27336412-A675C775-46D5-4024-AE9C-55EBF24EF4F9 Q30833191-1FF4063A-9B88-49BB-9F7D-341E371FB13B Q33604701-B39733CE-AAFF-4FCF-8F75-690EC68F7E17 Q33893649-C96F246C-759A-4D0F-8873-DC2F9975D082 Q33954912-7D74B825-DA97-44B2-8E7B-8444D9D15192 Q34061413-24D7D6C7-EF3D-4678-9415-B73390E5CFAE Q35587581-48B4EF93-0EC6-4B65-A909-DD61E6A74790 Q36433782-9A230DA9-18F9-4756-AF71-694E7EC550C2 Q36976259-75B7C40A-E417-44F9-9114-82796AF54D02 Q37427319-C0A88CA5-BCFD-4312-B927-DE1A22E635EB Q37467536-670D603A-AD11-4754-8D6E-8C399B503C42 Q38102324-88F30746-C4EE-4ED7-8619-EF1577B12077 Q38793026-4C923C58-FB38-4E0E-A882-CE51335735C0 Q38845649-143A2FCA-980F-4BEF-8DD7-B86D096685DB Q38936426-75FF7E13-1599-4DA4-9C8E-9C936B2AB73A Q39169261-081E8F4B-1A4E-4443-BE5A-A605D105160B Q39345035-26FEABEF-B75C-48AD-AB02-85186BA7CD4D Q41927946-9AEB67A1-0EBC-41CD-A088-ECC11B34A967 Q47165265-D53D7C6B-B9FE-452A-A36E-257518DAB817 Q48020232-644D02AC-902D-4897-87C9-20EA54928323 Q53841357-334BC576-7B8C-4F78-ABDB-F6E49562D2D1 Q54305936-D2DFA566-AB31-4B25-A3A4-D346FCA6E24B Q55193274-FFB245B0-9519-46BC-864C-38C3904EA4A9

P2860

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

http://www.wikidata.org/entity/Q42132761

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@en

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@nl

type

label

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@en

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@nl

prefLabel

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@en

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@nl

P1433

Q42132761-26C9AC2B-5C8F-4639-AD7D-C83DDB39037C

P1476

Q42132761-DD80E597-D883-4E43-B357-98F5EF0AAE50

P2093

Q42132761-15B26001-AEDC-4501-B007-A6BC5EFFC438

Q42132761-54655B94-4A52-44FF-90E0-2748950E08F0

Q42132761-845E8F06-D26B-45C8-8394-A01BAC14BAF9

Q42132761-927B9E6D-D86B-4E5F-8670-DD5C0E3D227E

Q42132761-9669683F-796B-4816-A3E0-9DAA664AACBA

Q42132761-A685EA29-FA30-43A8-A28D-6A3F2161C3D8

Q42132761-B3702246-C9FE-4BF0-8E9A-7177E18E4502

Q42132761-B46EEA89-61C1-41B5-BE8F-E6A1C70B9D5C

Q42132761-C76880F7-2C52-4E52-866E-E8130B9C189D

P2860

Q42132761-138151DC-0CB5-42AA-81C2-93BA5EF771D2

Q42132761-1DA9D936-215D-48B5-B934-324DEA26084A

Q42132761-203D0C4B-F81F-45F1-A314-43E93ADE15DD

Q42132761-27B90939-7F46-48D1-A397-0941CAAE4B34

Q42132761-28743051-1668-4005-BE32-3AA1D1E77A8B

Q42132761-2D801EFC-A0BF-47E6-A1E3-1494C3E60ECF

Q42132761-2FE66AFE-D189-4B36-A330-4AC9AC83DDC0

Q42132761-317B6BEE-8DB4-47CE-AED7-48F528D086EA

Q42132761-3399397B-23F0-44EE-A14F-C8038AC77FE4

Q42132761-33A0040E-3849-4926-8D6F-50BB3A3941DE

P304

Q42132761-6B94BBA3-FB10-47E2-A274-79A2A24F00BE

P31

Q42132761-49112FF4-9148-414C-8A96-2745082FF54E

P356

Q42132761-A22DD7F5-E75F-479B-9C66-FC802726F276

P407

Q42132761-BDFDE137-6F10-40B7-85A3-ECD48341F03B

P478

Q42132761-A53A00C9-2956-45EF-B869-C487031BFCC5

P577

Q42132761-D96C89AF-6AF7-4AD7-AFCA-9BC594F19CE6

P5875

Q42132761-6AA37A53-B6C8-40D1-A366-66DD4E0217E2

P698

Q42132761-CD7F6568-B13E-4D1A-A492-196454E358DC

P921

Q42132761-8362A5C2-17C4-4288-B7C0-6A51BDF183CD

P932

Q42132761-9C149E49-F4E2-41D2-B3E7-B23DD928A324

P356

J.NEUROSCIENCE.2012.07.018

P1433

P1476

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats

@en

P2093

A Zacharek

http://www.w3.org/2001/XMLSchema#string

C Roberts

http://www.w3.org/2001/XMLSchema#string

C Zhang

http://www.w3.org/2001/XMLSchema#string

J Chen

http://www.w3.org/2001/XMLSchema#string

M Chopp

http://www.w3.org/2001/XMLSchema#string

M Lu

http://www.w3.org/2001/XMLSchema#string

R Ning

http://www.w3.org/2001/XMLSchema#string

T Yan

http://www.w3.org/2001/XMLSchema#string

X Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

Inflammatory mechanisms of diabetic complications.

Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats.

Inflammatory mediators and stroke: new opportunities for novel therapeutics.

Toll-like receptor 4 in CNS pathologies

A rat model of studying tissue-type plasminogen activator thrombolysis in ischemic stroke with diabetes.

Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview.

Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.

Advanced glycation endproducts (AGEs) as uremic toxins.

P304

326-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROSCIENCE.2012.07.018

http://www.w3.org/2001/XMLSchema#string

P407

P478

222

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229436287

http://www.w3.org/2001/XMLSchema#string

P698

22820263

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3474540

http://www.w3.org/2001/XMLSchema#string